{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T21:56:18Z","timestamp":1648763778252},"reference-count":26,"publisher":"Pharmaceutical Society of Japan","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2021,6,1]]},"DOI":"10.1248\/bpb.b20-00691","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T22:14:28Z","timestamp":1622499268000},"page":"762-770","source":"Crossref","is-referenced-by-count":0,"title":["Prediction of the Area under the Curve Using Limited-Point Blood Sampling in a Cocktail Study to Assess Multiple CYP Activities"],"prefix":"10.1248","volume":"44","author":[{"given":"Motoyasu","family":"Miura","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice & Science, School of Pharmaceutical Sciences, University of Shizuoka"},{"name":"Hospital Pharmacy, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimako","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice & Science, School of Pharmaceutical Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice & Science, School of Pharmaceutical Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Kamiya","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Katayama","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Hakamata","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Odagiri","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Inui","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Namiki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice & Science, School of Pharmaceutical Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) Michalets EL. Update: clinically significant cytochrome P-450, drug interactions. <i>Pharmacotherapy<\/i>, <b>18<\/b>, 84\u2013112 (1998)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Nebert DW, Russell DW. Clinical importance of the cytochromes P450. <i>Lancet<\/i>, <b>360<\/b>, 1155\u20131162 (2002).","DOI":"10.1016\/S0140-6736(02)11203-7"},{"key":"3","unstructured":"3) Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. <i>J. Pharmacol. Exp. Ther.<\/i>, <b>270<\/b>, 414\u2013423 (1994)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Guengerich FP. Influence of nutrients and other dietary materials on cytochrome P-450 enzymes. <i>Am. J. Clin. Nutr.<\/i>, <b>61<\/b> (Suppl.), 651S\u2013658S (1995).","DOI":"10.1093\/ajcn\/61.3.651S"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Bebia Z, Buch SC, Wilson JW, Frye RF, Romkes M, Cecchetti A, Chaves-Gnecco D, Branch RA. Bioequivalence revisited: influence of age and sex on CYP enzymes. <i>Clin. Pharmacol. Ther.<\/i>, <b>76<\/b>, 618\u2013627 (2004).","DOI":"10.1016\/j.clpt.2004.08.021"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA. Validation of the five-drug \u2018Pittsburgh cocktail\u2019 approach for assessment of selective regulation of drug metabolizing enzymes. <i>Clin. Pharmacol. Ther.<\/i>, <b>62<\/b>, 365\u2013376 (1997).","DOI":"10.1016\/S0009-9236(97)90114-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS Jr. Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6 and 3A, <i>N<\/i>-acetyltransferase-2, and xanthine oxidase with the \u201cCooperstown 5\u2009+\u20091 cocktail.\u201d <i>Clin. Pharmacol. Ther.<\/i>, <b>74<\/b>, 437\u2013447 (2003).","DOI":"10.1016\/S0009-9236(03)00229-7"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Christensen M, Andersson K, Dal\u00e9n P, Mirghani RA, Muirhead GJ, Nordmark A, Tybring G, Wahlberg A, Ya\u015far U, Bertilsson L. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. <i>Clin. Pharmacol. Ther.<\/i>, <b>73<\/b>, 517\u2013528 (2003).","DOI":"10.1016\/S0009-9236(03)00050-X"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Ryu JY, Song IS, Sunwoo YE, Shon JH, Liu KH, Cha IJ, Shin JG. Development of the \u201cInje cocktail\u201d for high-throughput evaluation of five human cytochrome P450 isoforms <i>in vivo.<\/i> <i>Clin. Pharmacol. Ther.<\/i>, <b>82<\/b>, 531\u2013540 (2007).","DOI":"10.1038\/sj.clpt.6100187"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Inui N, Akamatsu T, Uchida S, Tanaka S, Namiki N, Karayama M, Chida K, Watanabe H. Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method. <i>Clin. Pharmacol. Ther.<\/i>, <b>94<\/b>, 702\u2013708 (2013).","DOI":"10.1038\/clpt.2013.167"},{"key":"11","unstructured":"11) U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). (2017). \u201cClinical drug interaction studies\u2014study design, data analysis, and clinical implications guidance for industry.\u201d: \u2039https:\/\/www.fda.gov\/media\/82734\/download\u203a, accessed 1 December, 2019."},{"key":"12","unstructured":"12) European Medicines Agency. (2015). \u201cGuideline on the investigation of drug interactions.\u201d: \u2039https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf\u203a, accessed 14 April, 2020."},{"key":"13","unstructured":"13) The Ministry of Health. Labour and Welfare (2018). \u201cGuideline on drug interaction for drug development and appropriate provision of information.\u201d: \u2039https:\/\/www.pmda.go.jp\/files\/000228122.pdf\u203a, accessed 1 December, 2019."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Coelho EB, Cusinato DAC, Ximenez JP, Lanchote VL, Struchiner CJ, Suarez-Kurtz G. Limited sampling modeling for estimation of phenotypic metrics for CYP enzymes and the ABCB1 transporter using a cocktail approach. <i>Front. Pharmacol.<\/i>, <b>11<\/b>, 22 (2020).","DOI":"10.3389\/fphar.2020.00022"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Derungs A, Donzelli M, Berger B, Noppen C, Kr\u00e4henb\u00fchl S, Haschke M. Effects of cytochrome P450 inhibition and induction on the phenotyping metrics of the basel cocktail: a randomized crossover study. <i>Clin. Pharmacokinet.<\/i>, <b>55<\/b>, 79\u201391 (2016).","DOI":"10.1007\/s40262-015-0294-y"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) de Andr\u00e9s F, Ter\u00e1n S, Bovera M, Fari\u00f1as H, Ter\u00e1n E, LLerena A. Multiplex phenotyping for systems medicine: a one-point optimized practical sampling strategy for simultaneous estimation of CYP1A2, CYP2C9, CYP2C19, and CYP2D6 activities using a cocktail approach. <i>OMICS<\/i>, <b>20<\/b>, 88\u201396 (2016).","DOI":"10.1089\/omi.2015.0131"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Bosilkovska M, Samer CF, D\u00e9glon J, Rebsamen M, Staub C, Dayer P, Walder B, Desmeules JA, Daali Y. Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots. <i>Clin. Pharmacol. Ther.<\/i>, <b>96<\/b>, 349\u2013359 (2014).","DOI":"10.1038\/clpt.2014.83"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Tanaka S, Uchida S, Inui N, Takeuchi K, Watanabe H, Namiki N. Simultaneous LC-MS\/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 substrate drugs and their metabolites. <i>Biol. Pharm. Bull.<\/i>, <b>37<\/b>, 18\u201325 (2014).","DOI":"10.1248\/bpb.b13-00401"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. <i>J. Pharmacokinet. Biopharm.<\/i>, <b>9<\/b>, 503\u2013512 (1981).","DOI":"10.1007\/BF01060893"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Rodighiero V. Effects of liver disease on pharmacokinetics. An update. <i>Clin. Pharmacokinet.<\/i>, <b>37<\/b>, 399\u2013431 (1999).","DOI":"10.2165\/00003088-199937050-00004"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Jones AE, Brown KC, Werner RE, Gotzkowsky K, Gaedigk A, Blake M, Hein DW, van der Horst C, Kashuba AD. Variability in drug metabolizing enzyme activity in HIV-infected patients. <i>Eur. J. Clin. Pharmacol.<\/i>, <b>66<\/b>, 475\u2013485 (2010).","DOI":"10.1007\/s00228-009-0777-6"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Nazir S, Iqbal Z, Ahmad L, Shah Y, Nasir F. Pharmacokinetics of omeprazole and its metabolites in three phases of menstrual cycle. <i>Eur. J. Drug Metab. Pharmacokinet.<\/i>, <b>40<\/b>, 13\u201322 (2015).","DOI":"10.1007\/s13318-013-0167-4"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, Hall SD. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. <i>Clin. Pharmacol. Ther.<\/i>, <b>74<\/b>, 275\u2013287 (2003).","DOI":"10.1016\/S0009-9236(03)00187-5"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Kamiya C, Inui N, Hakamata A, Miyakawa S, Tanaka S, Uchida S, Namiki N, Odagiri K, Watanabe H. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype. <i>J. Pharmacol. Sci.<\/i>, <b>139<\/b>, 361\u2013366 (2019).","DOI":"10.1016\/j.jphs.2019.03.001"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Zhu B, Ou-Yang DS, Chen XP, Huang SL, Tan ZR, He N, Zhou HH. Assessment of cytochrome P450 activity by a five-drug cocktail approach. <i>Clin. Pharmacol. Ther.<\/i>, <b>70<\/b>, 455\u2013461 (2001).","DOI":"10.1067\/mcp.2001.119813"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Donzelli M, Derungs A, Serratore M-G, Noppen C, Nezic L, Kr\u00e4henb\u00fchl S, Haschke M. The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots. <i>Clin. Pharmacokinet.<\/i>, <b>53<\/b>, 271\u2013282 (2014).","DOI":"10.1007\/s40262-013-0115-0"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/6\/44_b20-00691\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T04:49:00Z","timestamp":1622868540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/6\/44_b20-00691\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b20-00691","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]}}}